Regulation of cellular cytoskeleton by the soluble LDL receptor family with the application for novel anti-atherosclerosis therapy

可溶性低密度脂蛋白受体家族对细胞骨架的调节及其在新型抗动脉粥样硬化治疗中的应用

• 批准号: 21390277
• 负责人: BUJO Hideaki
• 金额: $ 11.07万
• 依托单位: Chiba University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21390277/
• 关键词: 脂質代謝異常; 単球; 平滑筋細胞; 細胞遊走; LR11; 細胞骨格; 脂肪細胞; 運動能; 動脈硬化; 血管傷害

Soluble form of LR11, a member of LDL receptor family, plays an important role in the pathological phenotypic conversion of intimal smooth muscle cells. The aim of study was to clarify the mechanism underlying the regulation of cytoskeleton reorganization to achieve the acceleration of cellular migration and adhesion through the LR11-mediated pathways, the involvement of sLR11 in various diseases, and the basic significance for the development of novel therapy against atherosclerosis. The results obtained from the cell-biological, animal or patient analysis has shown that soluble LR11 is important for the common mechanism underlying the migration for floating cells as well as attached cells, the differentiation of adipocytes, and the development of vascular injury. These results suggested that the target regulation focused on the molecule contributes to the development of novel therapy to regulate the cell migration in the fields of atherosclerosis and also in other diseases.

LR11是LDL受体家族的一员，可溶形式的LR11在内膜平滑肌细胞的病理表型转变中发挥着重要作用。研究目的是阐明通过LR11介导的途径调节细胞骨架重组以实现细胞迁移和粘附加速的机制，sLR11在多种疾病中的参与，以及对开发针对该疾病的新疗法的基本意义。动脉粥样硬化。从细胞生物学、动物或患者分析中获得的结果表明，可溶性LR11对于漂浮细胞和贴壁细胞迁移、脂肪细胞分化和血管损伤发展的共同机制很重要。这些结果表明，针对该分子的靶标调节有助于开发新疗法，以调节动脉粥样硬化和其他疾病领域的细胞迁移。

项目成果

Interrelations between CSF soluble APP, amyloid-b 1-42, SORL1, and tau levels in Alzheimer's disease

阿尔茨海默病中脑脊液可溶性 APP、淀粉样蛋白-b 1-42、SORL1 和 tau 水平之间的相互关系

• 发表时间: 2011
• 期刊: J Alzheimers Dis
• 影响因子: 4
• 作者: Alexopoulos P;Luo L-H;Tsolakidou A;Kratzer M;Grimmer T;Westerteicher C;Jiang M;Bujo H;Diehl-Schmid J;Kurz A;Perneczky R
• 通讯作者: Perneczky R

SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer's disease

• DOI: 10.1007/s00406-012-0295-x
• 发表时间: 2012-09-01
• 期刊: EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
• 影响因子: 4.7
• 作者: Guo, Liang-Hao;Westerteicher, Christine;Perneczky, Robert
• 通讯作者: Perneczky, Robert

Fibrin glue is a candidate scaffold for long-term therapeutic protein expression in spontaneously differentiated adipocytes in vitro

• DOI: 10.1016/j.yexcr.2011.10.007
• 发表时间: 2012-01-01
• 期刊: EXPERIMENTAL CELL RESEARCH
• 影响因子: 3.7
• 作者: Aoyagi, Yasuyuki;Kuroda, Masayuki;Bujo, Hideaki
• 通讯作者: Bujo, Hideaki

Enhanced circulating solubule LR11 in patients with coronary organic stenosis.

冠状动脉器质性狭窄患者循环可溶性 LR11 增强。

• 发表时间: 2010
• 期刊: Atherosclerosis
• 影响因子: 5.3
• 作者: Takahashi M;Bujo H;Jiang M;Noike H;Saito Y;Shirai K.
• 通讯作者: Shirai K.

Crystallization and preliminary crystallographic anal-ysis of human LR11 Vps10p domain

人LR11 Vps10p结构域的结晶及初步晶体学分析

• DOI: 10.1107/s1744309110048153
• 发表时间: 2011
• 期刊: Acta Crystallogr Sect F Struct Biol Cryst Commun
• 作者: Nakata Z;Nagae M;Yasui N;Bujo H;Nogi T;Takagi J
• 通讯作者: Takagi J